Adrienn Menyhart

Dr. Adrienn Menyhart

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
BBBarbara Aniko Bordacs
Barbara Aniko Bordacs
ÁVÁkos Várkonyi
Ákos Várkonyi
ZVZsuzsanna Valkusz
Zsuzsanna Valkusz
SNSzabolcs Nyiraty
Szabolcs Nyiraty
APAnikó Pósa
Anikó Pósa
TVTamás Várkonyi
Tamás Várkonyi
The present study was conducted in type 1 diabetic (T1DM) patients to evaluate the metabolic and glycemic control as well as the manifestations of neuropathy. The impact of continuous glucose monitoring (CGM) on the measured parameters was also analyzed. A total of 61 T1DM patients (age: 42.5 ± 1.8 years, DM duration: 22.8 ± 1.6 years, mean ± SE) participated in the study. In total, 24 patients had CGM sensors and 37 did not. Cardiovascular autonomic neuropathy was assessed using cardiovascular reflex tests. Peripheral sensory function was evaluated by a Neurometer and calibrated tuning fork on the upper and lower limbs. Metabolic status was characterized by the determination of triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL), total cholesterol, and glycated haemoglobin (HbA1c). A positive correlation was found between HbA1c and triglyceride levels (r = 0.28, p < 0.05). CGM users and non-users differed in triglyceride (0.9 ± 0.1 vs. 1.24 ± 0.12 mmol/L, p < 0.05), HDL cholesterol (1.7 ± 0.1 vs. 1.4 ± 0.1 p < 0.05 mmol/L), and HbA1c (7.5 ± 0.2 vs. 8.3 ± 0.3%, p < 0.05) levels as well. Significant differences were found for the Valsalva ratio, Neurometer, and calibrated tuning fork results between CGM users and non-users. This study found a significant correlation between HbA1c and triglyceride levels in T1DM. CGM use resulted in improved metabolic parameters and less autonomic and sensory nerve damage. As a novel finding, CGM is presumed to prevent both micro-, and macrovascular complications and, by this way, potentially reducing mortality rates.

11 August 2026 in Medicina
Verified
Journal Article
Open access
PDF file
DBDóra Marietta Balogh
Dóra Marietta Balogh
KOKarola Osgyán
Karola Osgyán
MBMagdolna Békeffy
Magdolna Békeffy
MKMiklós Kempler
Miklós Kempler
GBGergely Balaton
Gergely Balaton
Adrienn MenyhartAdrienn Menyhart
Adrienn Menyhart
Background and Objectives: To determine whether continuous glucose monitoring (CGM)-derived metrics can differentiate between normoglycemia, increased diabetes risk (FINDRISC+) and prediabetes and to assess whether CGM-derived metrics provide additional discriminatory information beyond conventional laboratory markers. Materials and Methods: In this cross-sectional study, 41 adults without diabetes were classified as normoglycemic controls (HbA1c < 5.7%, FINDRISC < 12), individuals at increased diabetes risk (HbA1c < 5.7%, FINDRISC ≥ 12), or individuals with prediabetes (HbA1c 5.7–6.49%). All participants underwent 14-day CGM. Mean interstitial glucose, glycemic variability (SD, CV) and time in, above and below range (TIR, TAR, TBR) were analyzed. Group differences were assessed using ANOVA or non-parametric tests; correlations were evaluated using Pearson analysis. Results: HbA1c differed significantly across groups (F = 17.62; p < 0.001). Among CGM metrics, only mean interstitial glucose differed (F = 3.54; p = 0.039), driven by higher values in the prediabetes group. Glycemic variability and time-based metrics did not differ significantly. Substantial overlap was observed between the increased risk and prediabetes groups. No significant correlation was found between HbA1c and mean CGM glucose (r = 0.164; p = 0.30). Conclusions: In this exploratory cohort, short-term CGM-derived metrics provided limited additional discriminatory information beyond conventional laboratory markers and clinical risk assessment. Larger prospective studies are needed to determine the discriminatory and predictive value of CGM in early metabolic risk states.

15 August 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
FSFerenc Sztanek
Ferenc Sztanek
APAttila Pető
Attila Pető
LTLászló Imre Tóth
László Imre Tóth
Hajnalka LőrinczHajnalka Lőrincz
Hajnalka Lőrincz
ÁMÁgnes Molnár
Ágnes Molnár
ANAttila Nagy
Attila Nagy
Background/Objectives: Diabetic sensorimotor polyneuropathy (DSPN) is a frequent microvascular complication of diabetes mellitus, associated with increased morbidity and reduced quality of life. The existing literature offers a limited understanding of sex-specific cardiovascular risk profiles and their association with DSPN, particularly within Central and Eastern European populations. Methods: A retrospective analysis was conducted using data from 621 individuals with type 1 or type 2 diabetes mellitus who underwent comprehensive neuropathy screening at the University of Debrecen between 2017 and 2021. The diagnosis of DSPN was made in accordance with international criteria, incorporating symptom scores, and electrophysiological measurements. Multivariate logistic regression was applied in order to identify independent predictors. Results: The diagnosis of DSPN was made in 444 individuals (71.5%), of whom 58.2% were female. Despite similar glycemic control (HbA1c: 7.81% in men vs. 7.65% in women, p = 0.297), men had significantly more frequent occurrences of previous myocardial infarction (11.8% vs. 5.0%, p = 0.008), peripheral vascular disease (19.9% vs. 12.7%, p = 0.041) and atherosclerosis (31.7% vs. 22.0%, p = 0.021). Multivariate analysis showed that female gender was independently associated with a lower incidence of DSPN (odds ratio [OR] = 0.592, 95% confidence interval [CI]: 0.369–0.950, p = 0.030), while diabetic retinopathy was a significant predictor (OR = 2.728, 95% CI: 1.300–5.725, p = 0.008). Electrophysiological testing revealed lower nerve conduction amplitudes in females for selected nerves. Conclusions: Our findings highlight sex-specific differences in neuropathy risk and support the implementation of individualized screening strategies in diabetic populations with region-specific risk factors.